Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DNTH Dianthus Therapeutics Inc.

已收盘 08-06 16:00:00 EDT

109.92

-2.58

-2.29%

盘后109.92

+0.000.00%

19:40 EDT

最高114.14	最低106.86	成交量70.84万
今开111.93	昨收112.50	日振幅6.47%
总市值61.48亿	流通市值61.41亿	总股本5,593万
成交额7,769万	换手率1.27%	流通股本5,587万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":109.92,"timestamp":1786046400000,"preClose":112.5,"halted":0,"volume":708363,"hourTrading":{"tag":"盘后","latestPrice":109.92,"preClose":109.92,"latestTime":"19:40 EDT","volume":159876,"amount":17573544.52,"timestamp":1786059620335,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02293333333333332,"floatShares":55865100,"shares":55934399,"eps":-4.166697,"marketStatus":"已收盘","change":-2.58,"latestTime":"08-06 16:00:00 EDT","open":111.93,"high":114.14,"low":106.86,"amount":77692443.472728,"amplitude":0.064711,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.166697,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786089600000},"marketStatusCode":5,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":112.5,"preHourTrading":{"tag":"盘前","latestPrice":113.6,"preClose":112.5,"latestTime":"09:29 EDT","volume":1399,"amount":158023.12166,"timestamp":1786022967001,"change":1.1,"changeRate":0.009778,"amplitude":0.146667},"postHourTrading":{"tag":"盘后","latestPrice":109.92,"preClose":109.92,"latestTime":"19:40 EDT","volume":159876,"amount":17573544.52,"timestamp":1786059620335,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.780889,"impliedVol":0.5139,"impliedVolPercentile":0.1036},"requestUrl":"/m/hq/s/DNTH","defaultTab":"news","newsList":[{"id":"1122665642","title":"Dianthus Therapeutics 披露截至2026年6月30日现金储备达12亿美元，预期运营资金可持续至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1122665642","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122665642?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:37","pubTimestamp":1785875839,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 最新披露，截至2026年6月30日，公司持有现金储备高达12亿美元。基于当前资金状况，管理层预期这一现金跑道将支持公司运营直至2030年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186641577","title":"Dianthus Therapeutics 旗下 Dnth312 靶向抑制 Ac1s 与 Baff/April 通路，布局自身免疫疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1186641577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186641577?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841890,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics 公司正着力推进其核心候选药物 Dnth312。该药物旨在通过抑制 Ac1s 以及 Baff/April 这两条关键信号通路，为自身免疫性疾病患者提供全新的治疗策略。此举展现了公司在免疫调节领域的前沿探索与雄心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111288447","title":"Dianthus Therapeutics：DNTH312在非人灵长类模型中展现与Povetacicept相当的免疫球蛋白降低效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1111288447","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111288447?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:11","pubTimestamp":1785841869,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，其候选药物 DNTH312 在非人灵长类动物（NHPs）研究中，显示出与 Povetacicept 相似的免疫球蛋白降低能力。这一发现表明，DNTH312 在调节免疫反应方面具有潜在的治疗价值。该研究的详细数据尚未完全公布，但初步结果已为后续的临床开发提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120010877","title":"异动解读｜Dianthus Therapeutics盘中上涨9.22%，报104.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120010877","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120010877?lang=zh_cn&edition=full","pubTime":"2026-07-18 02:51","pubTimestamp":1784314270,"startTime":"0","endTime":"0","summary":"7月18日，Dianthus Therapeutics盘中上涨9.22%，报104.14美元/股，成交额7534.37万美元。Dianthus Therapeutics所在的生物科技行业中，个股中，艾伯维公司涨0.57%，安进跌2.31%，吉利德科学跌1.37%，福泰制药跌0.37%，再生元制药公司跌0.67%。Dianthus Therapeutics是一家临床阶段的生物技术公司，致力于设计和提供新型单克隆抗体，与现有的补体疗法相比，其选择性和效力更高。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154707624","title":"Dianthus Therapeutics预计2026年第四季度公布Momentum试验2期顶线数据，Captivate项目更新将于2026年内完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1154707624","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154707624?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:01","pubTimestamp":1782730911,"startTime":"0","endTime":"0","summary":"生物技术公司Dianthus Therapeutics Inc.近日更新了其关键研发管线的时间表。公司宣布，其备受关注的Momentum试验2期研究的顶线数据预计将在2026年第四季度公布。这项试验是评估其候选疗法在特定适应症中有效性与安全性的重要里程碑。与此同时，公司还透露了另一项名为Captivate的项目的进展。关于Captivate的更新信息预计将在2026年年内完成并对外公布。上述进展预计将对公司的未来发展方向和潜在价值产生重要影响。市场将持续关注Dianthus Therapeutics在这些关键时间点所披露的数据与信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187316053","title":"Dianthus Therapeutics宣布启动Claseprubart治疗全身型重症肌无力的III期EMERGE试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187316053","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187316053?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:01","pubTimestamp":1782730878,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 已正式启动其候选药物claseprubart用于治疗全身型重症肌无力（gMG）的III期EMERGE临床试验。该试验旨在评估claseprubart在这一自身免疫性神经肌肉疾病中的疗效与安全性，标志着该药物研发进程中的一个关键里程碑。全身型重症肌无力是一种导致肌肉无力和疲劳的慢性疾病，对患者生活质量有显著影响。此次III期试验的启动，是基于先前临床研究获得的积极数据，为潜在的新治疗方案带来了希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109161041","title":"异动解读 | 获多家机构上调评级与目标价，Dianthus Therapeutics盘中大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109161041","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109161041?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:54","pubTimestamp":1773161689,"startTime":"0","endTime":"0","summary":"生物制药公司Dianthus Therapeutics Inc.今日盘中股价大幅上涨5.09%，引起市场关注。消息面上，投资机构Raymond James宣布将Dianthus Therapeutics的股票评级从“跑赢大盘”上调至“强力买入”，并将其目标股价从63美元大幅调高至123美元。机构分析通常基于对公司基本面、研发管线及市场潜力的评估，评级和目标价的上调往往会吸引投资者买入，从而推高股价。Dianthus Therapeutics作为一家生物制药公司，其股价对这类研究行动反应敏感。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109692385","title":"Raymond James将Dianthus Therapeutics评级上调至强力买入，目标价大幅提升至123美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109692385","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109692385?lang=zh_cn&edition=full","pubTime":"2026-03-10 19:29","pubTimestamp":1773142181,"startTime":"0","endTime":"0","summary":"投资机构Raymond James宣布，将生物制药公司Dianthus Therapeutics Inc.（DNTH）的股票评级从“跑赢大盘”上调至“强力买入”。与此同时，该机构将其目标股价从原先的63美元显著调高至123美元，显示出对该公司未来增长前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161802372","title":"Dianthus Therapeutics盘后股价下挫4.1%，宣布拟进行4亿美元承销公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1161802372","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161802372?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:37","pubTimestamp":1773088629,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (DNTH) 在盘后交易时段股价下跌4.1%。该公司同时宣布，计划进行一笔价值4亿美元的承销公开发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184186272","title":"Dianthus Therapeutics Inc. 计划将净收益用于临床、商业、营运资本及公司一般用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1184186272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184186272?lang=zh_cn&edition=full","pubTime":"2026-03-10 04:02","pubTimestamp":1773086531,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，公司拟将此次融资的净收益主要用于支持其临床项目推进、商业活动拓展、营运资本补充以及其他一般公司用途。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133599026","title":"Dianthus Therapeutics公布近期业务进展，包括三期Captivate CIDP试验启动决定及2025财年第四季度和全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1133599026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133599026?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:11","pubTimestamp":1773054673,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (以下简称Dianthus Therapeutics) 近日重点通报了其近期的多项业务里程碑。其中，最引人注目的是公司已正式决定推进其关键性三期临床试验——Captivate CIDP研究。此举标志着其在慢性炎症性脱髓鞘性多发性神经根神经病（CIDP）治疗领域的研发迈入决定性阶段。\n与此同时，该公司还公布了2025财年第四季度及全年的财务报告，详细披露了期间的财务状况与运营表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124943604","title":"Dianthus Therapeutics独立数据安全监查委员会审查确认试验推进决定，未发现相关严重感染或不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1124943604","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124943604?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:05","pubTimestamp":1773054301,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 宣布，其独立数据安全监查委员会（DSMB）的审查结果已确认试验可继续推进。此次审查确认，试验过程中未出现任何与治疗方案相关的严重感染或不良事件。\n这一积极结果进一步支持了该临床试验的安全性评估，为后续研究阶段的顺利开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154201489","title":"Dianthus Therapeutics宣布：基于CIDP三期试验中期分析结果，决定提前推进Claseprubart研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1154201489","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154201489?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054141,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. (DNTH) 近日公布了一项重要研发进展。针对其在研药物Claseprubart用于治疗慢性炎症性脱髓鞘性多发性神经病（CIDP）的三期临床试验（CAPTIVATE研究），公司已完成一项预设的中期应答者分析。基于该分析获得的积极数据，Dianthus Therapeutics已做出“提前推进”的决策，将继续推进该临床试验的进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108401230","title":"Dianthus Therapeutics维持300毫克/2毫升皮下注射每两周一次的剂量；计划取消600毫克/4毫升剂量组","url":"https://stock-news.laohu8.com/highlight/detail?id=1108401230","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108401230?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:02","pubTimestamp":1773054132,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. 决定继续采用其300毫克/2毫升的皮下注射方案，该方案为每两周给药一次。与此同时，公司计划停止其600毫克/4毫升的皮下注射剂量组，该组同样为每两周一次的给药频率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616531388","title":"Dianthus Therapeutics, Inc.盘中异动 早盘股价大跌5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616531388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2616531388?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:31","pubTimestamp":1772548314,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时31分，Dianthus Therapeutics, Inc.股票出现波动，股价急速下挫5.77%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.94%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段的生物技术公司，致力于设计和提供新型单克隆抗体，与现有的补体疗法相比，其选择性和效力更高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303223155a69dff2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","BK4007","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517494669","title":"Dianthus Therapeutics, Inc.盘中异动 大幅拉升9.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517494669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517494669?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185055,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Dianthus Therapeutics, Inc.股票出现异动，股价急速拉升9.52%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223056abe9b05d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516308756","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速下挫5.00%报20.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516308756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516308756?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:07","pubTimestamp":1741014460,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时07分，Dianthus Therapeutics, Inc.股票出现波动，股价大幅下跌5.00%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230741989a1a32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387469","title":"Dianthus Therapeutics, Inc.盘中异动 临近午盘大幅拉升5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514387469?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:40","pubTimestamp":1740674403,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时40分，Dianthus Therapeutics, Inc.股票出现异动，股价大幅拉升5.19%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.61%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004003abdf8d22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514566358","title":"Dianthus Therapeutics, Inc.盘中异动 早盘急速拉升7.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514566358?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580275,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分，Dianthus Therapeutics, Inc.股票出现异动，股价快速拉升7.80%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223115abddec78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DNTH","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778530","title":"Dianthus Therapeutics, Inc.盘中异动 早盘快速跳水5.85%报22.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513778530?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:11","pubTimestamp":1740409876,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时11分，Dianthus Therapeutics, Inc.股票出现波动，股价急速跳水5.85%。Dianthus Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。Dianthus Therapeutics, Inc.公司简介：Dianthus Therapeutics Inc 是一家临床阶段生物技术公司，致力于设计和提供新型单克隆抗体，优化其选择性和效力并使其优于现有的补体疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231116a2521e62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.magentatx.com","stockEarnings":[{"period":"1week","weight":0.0808},{"period":"1month","weight":0.2053},{"period":"3month","weight":0.3163},{"period":"6month","weight":1.2167},{"period":"1year","weight":4.2966},{"period":"ytd","weight":1.7299}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Dianthus Therapeutics, Inc.于2015年6月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物技术公司，开发新药，为更多的患者带来骨髓移植的治疗能力。该公司打算成为移植医学领域的完全整合的发现，开发和商业公司。该公司相信产品组合将提供显著的商业协同效应。 该公司正在开发产品，以便可以单独使用或相互结合使用。因此，该公司的投资组合可以以适合患者疾病的方式使用，以便患者可以接受多于一种洋红疗法作为其个人移植旅程的一部分。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.175283},{"month":2,"riseRate":0.625,"avgChangeRate":0.224994},{"month":3,"riseRate":0.5,"avgChangeRate":0.049298},{"month":4,"riseRate":0.375,"avgChangeRate":-0.05024},{"month":5,"riseRate":0.625,"avgChangeRate":-0.041628},{"month":6,"riseRate":0.75,"avgChangeRate":0.021233},{"month":7,"riseRate":0.666667,"avgChangeRate":0.038404},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.004814},{"month":9,"riseRate":0.375,"avgChangeRate":0.056023},{"month":10,"riseRate":0.25,"avgChangeRate":-0.093611},{"month":11,"riseRate":0.5,"avgChangeRate":0.042669},{"month":12,"riseRate":0.25,"avgChangeRate":-0.158671}],"exchange":"NASDAQ","name":"Dianthus Therapeutics Inc.","nameEN":"Dianthus Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Dianthus Therapeutics Inc.,DNTH,Dianthus Therapeutics Inc.股票,Dianthus Therapeutics Inc.股票老虎,Dianthus Therapeutics Inc.股票老虎国际,Dianthus Therapeutics Inc.行情,Dianthus Therapeutics Inc.股票行情,Dianthus Therapeutics Inc.股价,Dianthus Therapeutics Inc.股市,Dianthus Therapeutics Inc.股票价格,Dianthus Therapeutics Inc.股票交易,Dianthus Therapeutics Inc.股票购买,Dianthus Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dianthus Therapeutics Inc.(DNTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Dianthus Therapeutics Inc.(DNTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}